These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29453020)

  • 1. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
    Chiang CE; Lin SY; Lin TH; Wang TD; Yeh HI; Chen JF; Tsai CT; Hung YJ; Li YH; Liu PY; Chang KC; Wang KL; Chao TH; Shyu KG; Yang WS; Ueng KC; Chu PH; Yin WH; Wu YW; Cheng HM; Shin SJ; Huang CN; Chuang LM; Lin SJ; Yeh SJ; Sheu WH; Lin JL
    J Chin Med Assoc; 2018 Mar; 81(3):189-222. PubMed ID: 29453020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
    Chiang CE; Ueng KC; Chao TH; Lin TH; Wu YJ; Wang KL; Sung SH; Yeh HI; Li YH; Liu PY; Chang KC; Shyu KG; Huang JL; Tsai CD; Hung HF; Liu ME; Chao TF; Cheng SM; Cheng HM; Chu PH; Yin WH; Wu YW; Chen WJ; Lai WT; Lin SJ; Yeh SJ; Hwang JJ
    J Chin Med Assoc; 2020 Jul; 83(7):587-621. PubMed ID: 32628427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension.
    Chiang CE; Wang TD; Ueng KC; Lin TH; Yeh HI; Chen CY; Wu YJ; Tsai WC; Chao TH; Chen CH; Chu PH; Chao CL; Liu PY; Sung SH; Cheng HM; Wang KL; Li YH; Chiang FT; Chen JH; Chen WJ; Yeh SJ; Lin SJ
    J Chin Med Assoc; 2015 Jan; 78(1):1-47. PubMed ID: 25547819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.
    Hong T; Su Q; Li X; Shan Z; Chen L; Peng Y; Chen L; Yan L; Bao Y; Lyu Z; Shi L; Wang W; Guo L; Ning G; Mu Y; Zhu D
    Diabetes Metab Res Rev; 2021 May; 37(4):e3416. PubMed ID: 33120435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes.
    Chiang CE; Ueng KC; Chao TH; Lin TH; Wu YJ; Wang KL; Sung SH; Yeh HI; Li YH; Liu PY; Chang KC; Shyu KG; Huang JL; Tsai CD; Hung HF; Liu ME; Chao TF; Cheng SM; Cheng HM; Chu PH; Yin WH; Wu YW; Chen WJ; Lai WT; Lin SJ; Yeh SJ; Hwang JJ; Hou CJ
    JACC Asia; 2021 Sep; 1(2):129-146. PubMed ID: 36338159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
    Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose targets for preventing diabetic kidney disease and its progression.
    Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
    PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.